Medical Device Industry Briefings
Daily-curated regulatory and market intelligence for overseas medical device brands entering China.
NMPA Accelerates Innovative Medical Device Approvals; NHSA Launches Pre-Pricing Pilot to Shorten Time-to-Market for China Market Entry
China's National Medical Products Administration (NMPA) has approved 51 innovative medical devices year-to-date in 2026 and pledged to further accelerate review pathways for emerging technologies including brain-computer interfaces. In parallel, the National Healthcare Security Administration (NHSA) launched a nationwide pre-pricing pilot that initiates pricing evaluation before market authorization, aiming to compress the lag between NMPA approval and clinical reimbursement for innovative medical technologies.
NMPA Tightens AI Medical Device Oversight: CMDE Revises AI Registration Guidance and Issues World's First BCI AI-EEG Dataset Standard
In mid-September 2026, China's Center for Medical Device Evaluation (CMDE) opened public consultation on the revised Artificial Intelligence Medical Device Registration Review Guidance and a new clinical evaluation guidance for AI multi-disease assisted decision devices. Separately, the NMPA published YY/T 2029-2026, the world's first industry standard for AI-processed EEG datasets used in brain-computer interface (BCI) medical devices, effective September 1, 2027.
NMPA Lays Out 15th Five-Year Plan for Innovative Medical Devices; 51 Innovative Devices Approved YTD
On September 20, 2026, NMPA Deputy Director Yang Sheng announced the 15th Five-Year Plan roadmap for innovative medical devices at a State Council Information Office press conference, revealing that 51 innovative medical devices have been approved year-to-date. The plan expands the 'Spring Rain Action' clinical-transformation program into frontier fields such as brain-computer interfaces, establishes market exclusivity for pediatric and rare-disease products, and explicitly encourages foreign manufacturers to produce high-end medical equipment domestically.
NMPA Unveils World's First BCI-EEG Dataset Standard; CMDE Opens AI Multi-Disease Device Guidance for Comment
On September 14, 2026, China's NMPA approved YY/T 2029—2026, the world's first industry standard for EEG datasets used by AI algorithms in brain-computer interface (BCI) medical devices, effective September 1, 2027. Two days later, CMDE opened for public comment a new clinical-evaluation guidance for AI-based multi-disease assisted-decision devices, alongside the 2026 revision of the overarching AI medical device registration guidance. The moves signal China's push to set global rules for AI-enabled and BCI medical devices.
DRG 3.0 Reshapes Hospital Economics; CMDE Opens 16 Class II IVD Guidelines for Comment
China's medical device sector this week faces converging pressures: DRG 3.0's finer grouping and robotic-surgery codes force device makers to prove value per case, while CMDE's 16 new Class II IVD guidelines and the full UDI rollout raise the compliance bar for registration and traceability.
NMPA Streamlines Class II Device Review Pathway; CMDE Releases New Technical Guidance
China's Center for Medical Device Evaluation (CMDE) released updated technical guidance for Class II medical device registration, introducing a streamlined documentation pathway expected to reduce average review timelines by 20-30%.
China Medical Device O2O Market Grows 28% YoY; Xiaoxiang Network Expands to 12,000 Stores
New industry data shows China's medical device online-to-offline (O2O) retail channel reached ¥18.4B in H1 2026, with the Xiaoxiang platform network expanding to over 12,000 connected retail pharmacies nationwide.